BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 1,470,000 shares, a decline of 13.5% from the January 15th total of 1,700,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Trading of BioVie

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp acquired a new position in shares of BioVie in the 4th quarter valued at approximately $34,000. NewEdge Advisors LLC raised its position in shares of BioVie by 14,000.0% in the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock valued at $28,000 after buying an additional 14,000 shares in the last quarter. Bank of Montreal Can acquired a new position in shares of BioVie in the 4th quarter valued at approximately $100,000. Geode Capital Management LLC raised its position in shares of BioVie by 223.3% in the 4th quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock valued at $247,000 after buying an additional 85,234 shares in the last quarter. Finally, Prosperity Wealth Management Inc. acquired a new position in shares of BioVie in the 4th quarter valued at approximately $63,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

BioVie Price Performance

BioVie stock traded up $0.06 during midday trading on Friday, hitting $1.83. The company’s stock had a trading volume of 255,845 shares, compared to its average volume of 779,341. BioVie has a 1-year low of $1.04 and a 1-year high of $33.10. The company has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $2.31. The company has a market cap of $33.77 million, a price-to-earnings ratio of -0.16 and a beta of 0.47.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.46) earnings per share for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.